Finally, as expected from these data, ITGA6A and ITGB4 expressions in CRC primary tumours have been explored as prognostic factors; l will also present rationale for using ITGA6 variants as biomarkers and data that confirm their validity for identifying patients with CRC lesions in a non-invasive mRNA-based stool test. This evidence concerns the gene ITGA6 and colorectal carcinoma.